Loading clinical trials...
Loading clinical trials...
Phase I Clinical Trial Evaluating the Toxicity, Pharmacokinetics and Biological Effect of Intravenous Bevacizumab (Avastin TM) in Combination With Escalating Doses of Oral AZD2171 for Patients With Advanced Malignancies
Conditions
Interventions
bevacizumab
cediranib maleate
Locations
1
United States
M D Anderson Cancer Center
Houston, Texas, United States
Start Date
May 1, 2007
Primary Completion Date
December 1, 2013
Last Updated
February 19, 2014
NCT07388563
NCT06561048
NCT04195633
NCT04925609
NCT00336063
NCT03278782
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions